<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02095587</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-145-14</org_study_id>
    <nct_id>NCT02095587</nct_id>
  </id_info>
  <brief_title>Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects</brief_title>
  <acronym>IPI-145-14</acronym>
  <official_title>A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Duvelisib in Subjects With Chronic Hepatic Impairment Compared to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SecuraBio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SecuraBio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics, safety, and tolerability of IPI-145 when administered to&#xD;
      subjects with chronic hepatic impairment and in matched healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a nonrandomized, open-label, parallel-group, single oral dose study in subjects with&#xD;
      chronic hepatic impairment and matched (age, sex, weight, BMI) healthy subjects. Subjects&#xD;
      will be enrolled into 1 of 3 groups based on hepatic impairment grade: mild, moderate and&#xD;
      normal hepatic function. An optional severe hepatic impairment group will enroll based on&#xD;
      data from the mild and moderate hepatic impairment groups in comparison to matched healthy&#xD;
      group. All subjects will receive a single oral dose of IPI-145 25 mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of IPI-145 and its primary metabolite, IPI-656</measure>
    <time_frame>Open 72 hours</time_frame>
    <description>PK parameters (AUC, Cmax and t1/2) of IPI-145 and its metabolite, IPI-656 Plasma concentrations of IPI-145 and its metabolite, IPI-656</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events following administration of IPI-145</measure>
    <time_frame>10 days</time_frame>
    <description>Safety Findings</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optional arm based on results from Arms 1, 2, and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-145</intervention_name>
    <description>25 mg single oral capsule</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_label>Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment</arm_group_label>
    <arm_group_label>Severe Hepatic Impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women of nonchildbearing potential between 18-70 years of age&#xD;
&#xD;
          -  Body Mass Index (BMI): 18.0 - 38.0 kg/m2.&#xD;
&#xD;
          -  Healthy subjects: in good health, determined by no clinically significant findings&#xD;
             from clinical evaluations&#xD;
&#xD;
          -  Hepatic impairment subjects: confirmed hepatic impairment &gt;1 year with etiology of&#xD;
             chronic alcoholism, chronic viral hepatitis (B or C), nonalcoholic steatohepatitis,&#xD;
             autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency, glycogen storage&#xD;
             diseases, or galactosemia&#xD;
&#xD;
          -  Provided written informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of childbearing potential&#xD;
&#xD;
          -  Hepatic impairment subjects: fluctuating or rapidly deteriorating hepatic function,&#xD;
             acute hepatitis, variceal bleeding within 8 weeks of screening, a history of&#xD;
             pancreatitis within 8 weeks of screening, evidence of hepatic encephalopathy &gt; Grade&#xD;
             1, current unstable hematologic condition, and/or creatinine clearance &lt; 60 mL/min&#xD;
&#xD;
          -  Healthy subjects: positive screening test for hepatitis B surface antigen, or&#xD;
             hepatitis C antibody&#xD;
&#xD;
          -  ECG at screening or Day -1 showing QTcF â‰¥ 450 msec for healthy subjects or &gt; 500 msec&#xD;
             for hepatically impaired subjects&#xD;
&#xD;
          -  Evidence of clinically significant medical conditions&#xD;
&#xD;
          -  History of gastrointestinal disease or surgery that may affect drug absorption&#xD;
&#xD;
          -  Positive or indeterminate QuantiFERON-TB Gold test at screening&#xD;
&#xD;
          -  Any active infection at the time of screening or admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 21, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

